Pacific Biosciences (PACB) 8.50 $PACB PacBio's SMRT

New Post Public Reply Private Reply Replies (0) Message Board

Apr 1, 2016 at 3:24 AM

Pacific Biosciences (PACB) 8.50 $PACB

PacBio's SMRT Sequencing Provides Scientists with a Superior Gorilla Genome Reference
GlobeNewswire - Thu Mar 31, 1:00PM CDT
Pacific Biosciences of California, Inc., (Nasdaq

ACB) the pioneer and leader in long-read sequencing using its Single Molecule, Real-Time (SMRT) technology, today announced that scientists from the University of Washington, the McDonnell Genome Institute at Washington University in St. Louis, and other institutions have published the best genome assembly of the gorilla to date -- more than 150-fold improvement over previous assemblies -- using long-read SMRT Sequencing from Pacific Biosciences. The peer-reviewed paper appears in the April 1 issue of the journal Science and is available online today.
PACB: 8.50 (-0.22)

Pacific Biosciences of California Shares Down 27.8% Since SmarTrend's Sell Call (PACB)
Comtex SmarTrend(R) - Thu Mar 24, 12:40AM CDT
SmarTrend identified a Downtrend for Pacific Biosciences of California (NASDAQ

ACB) on January 28th, 2016 at $10.73. In approximately 2 months, Pacific Biosciences of California has returned 27.83% as of today's recent price of $7.74.
PACB: 8.50 (-0.22)

Look for Shares of Pacific Biosciences of California to Potentially Pullback after Yesterday's 1.44% Rise
Comtex SmarTrend(R) - Mon Mar 21, 4:54PM CDT
Pacific Biosciences of California (NASDAQ

ACB) traded in a range yesterday that spanned from a low of $8.27 to a high of $8.73. Yesterday, the shares gained 1.4%, which took the trading range above the 3-day high of $8.66 on volume of 505,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
PACB: 8.50 (-0.22)

Is This the Biggest Threat Yet to Illumina?
Todd Campbell, The Motley Fool - Motley Fool - Fri Mar 18, 4:41PM CDT
IMAGE SOURCE: ILLUMINA INC. Illumina has held go-to status as the dominant maker of gene-sequencing devices for years, but a new, next-generation gene-sequencing machine made by Pacific Biosciences aims to change that. Can Illumina fend off...
PACB: 8.50 (-0.22), ILMN: 162.11 (+4.68)

Is It Time to Buy Illumina Inc. Stock?
Keith Speights, The Motley Fool - Motley Fool - Mon Mar 14, 10:39AM CDT
Image Source: Illumina It's been a rough winter for Illumina shareholders. The genomic sequencing company's stock plunged nearly 30% by early February before regaining some of those losses. However, Illumina's shares are still way down...
PACB: 8.50 (-0.22), TMO: 141.59 (+0.80), ILMN: 162.11 (+4.68)

Why Pacific Biosciences Lost 18.6% of Its Value Last Month
Todd Campbell, The Motley Fool - Motley Fool - Sat Mar 12, 9:21AM CST
SOURCE: PACIFIC BIOSCIENCES. What: Following a forecast for a slow launch schedule for its next generation gene sequencer and the admission that it will need more cash, shares in Pacific Biosciences tumbled 18.6% last month, according to ...
PACB: 8.50 (-0.22), ILMN: 162.11 (+4.68)

Shares of PACB Down 19.3% Since Downtrend Call on Shares
Comtex SmarTrend(R) - Thu Mar 03, 3:25PM CST
SmarTrend identified a Downtrend for Pacific Biosciences of California (NASDAQ

ACB) on January 28th, 2016 at $10.73. In approximately 1 month, Pacific Biosciences of California has returned 19.35% as of today's recent price of $8.65.
PACB: 8.50 (-0.22)

Biotechnology Equities Technical Commentary -- Relypsa, PDL BioPharma, Pacific Biosciences of California, and Clovis Oncology
ACCESSWIRE - Tue Feb 09, 7:02AM CST
NEW YORK, NY / ACCESSWIRE / February 9, 2016 / Park Lane Advisor has initiated coverage on the following equities: Relypsa Inc. (NASDAQ: RLYP), PDL BioPharma Inc. (NASDAQ: PDLI), Pacific Biosciences of California Inc. (NASDAQ: PACB), and Clovis Oncology Inc. (NASDAQ: CLVS). Free note on Relypsa can be accessed at http://www.parklaneadvisor.com/ On Monday, February 08, 2016, the NASDAQ Composite ended at 4,283.75, down 1.82%, the Dow Jones Industrial Average declined 1.10%, to finish the day at 16,027.05, and the S&P 500 closed at 1,853.44, down 1.42%. Register for your complimentary reports at the links given below.
PACB: 8.50 (-0.22), CLVS: 19.20 (-0.04), RLYP: 13.55 (+0.11), PDLI: 3.33 (+0.16)

Why Shares of Pacific Biosciences of California Plunged 23% Today
Travis Hoium, The Motley Fool - Motley Fool - Thu Feb 04, 11:21AM CST
What: Shares of gene sequencing company Pacific Biosciences of California plunged 23% in midday trading on Thursday after the company reported earnings that underwhelmed investors. So what: Fourth-quarter revenue surged 115% to $36.3 million...
PACB: 8.50 (-0.22)

Pacific Biosciences of California Doubles Revenue in Q4
Travis Hoium, The Motley Fool - Motley Fool - Thu Feb 04, 11:12AM CST
The sequencing business continues to hold a lot of promise for Pacific Biosciences of California , but it will take a little longer to start seeing its full potential. The company reported fourth-quarter 2015 earnings after the market closed on...
PACB: 8.50 (-0.22)

Pacific Biosciences (PACB) Stock Plunges on Q4 Loss
at The Street - Thu Feb 04, 10:04AM CST
Pacific Biosciences (PACB) stock is sinking in mid-morning trading on Thursday after the company reported a loss during the 2015 fourth quarter.
PACB: 8.50 (-0.22)

Pacific Biosciences Posts Q4 Loss, Stock Down on FY16 View
Zacks Equity Research - Zacks Investment Research - Thu Feb 04, 9:20AM CST
Pacific Biosciences of California Inc. (PACB) reported loss of 2 cents per share in the fourth quarter of 2015, in line with the Zacks Consensus Estimate.
ABMD: 94.81 (+1.78), PACB: 8.50 (-0.22), EXAC: 20.26 (+1.07), CRY: 10.75 (-0.40)

Downgrade Alert for Pacific Biosciences of California (PACB)
Comtex SmarTrend(R) - Thu Feb 04, 7:16AM CST
Pacific Biosciences of California (NASDAQ

ACB) was downgraded from Overweight to Neutral at Piper Jaffray today. The stock closed yesterday at $12.37 on volume of 3.9 million shares, above average daily volume of 2.6 million. Pacific Biosciences of California share prices have moved between a 52-week high of $14.00 and a 52-week low of $3.58 and closed yesterday at 246% above that low price at $12.37 per share. Over the last five market days, the 200-day moving average (MA) has gone up 1.1% while the 50-day MA has advanced 1.5%.
PACB: 8.50 (-0.22)

Pacific Biosciences' Q4 2015 net loss lowers to USD1.4m
M2 - Thu Feb 04, 4:07AM CST
Genetic analysis company Pacific Biosciences of California (NasdaqGS

ACB) stated on Wednesday its net loss of USD1.4m its fourth quarter ended 31 December 2015.
PACB: 8.50 (-0.22)

Pacific Biosciences reports 4Q loss
Automated Insights - Wed Feb 03, 3:47PM CST
MENLO PARK, Calif. (AP) _ Pacific Biosciences of California Inc. (PACB) on Wednesday reported a loss of $1.4 million in its fourth quarter.
PACB: 8.50 (-0.22)

Pacific Biosciences Announces Fourth Quarter 2015 Financial Results
GlobeNewswire - Wed Feb 03, 3:00PM CST
Pacific Biosciences of California, Inc. (NASDAQ

ACB) today announced financial results for its fourth quarter ended December 31, 2015.
PACB: 8.50 (-0.22)

Pacific Biosciences (PACB) Jumps: Stock Moves Up 24.3%
Zacks Equity Research - Zacks Investment Research - Wed Feb 03, 7:15AM CST
Pacific Biosciences of California, Inc. (PACB) shares rose above 24% in the last trading session.
PACB: 8.50 (-0.22)

Why Pacific Biosciences of California's Shares Popped 25% Today
Travis Hoium, The Motley Fool - Motley Fool - Tue Feb 02, 3:14PM CST
What: Shares of Pacific Biosciences of California surged as much as 37% in late trading today after rumors emerged of a potential buyout. With just minutes left in the trading day, shares had settled to a 25% gain. So what: Reuters is...
PACB: 8.50 (-0.22)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Ascletis Targets Obesity with New FDA Submission

Breaking Ground with Innovative Obesity Treatment In the world of biotech, where breakthroughs are hard-fought and the stakes can seem insurmountable, Ascletis Pharma is swinging for the fences with their latest maneuver. They've submitted an Investigational New Drug application to the U.S. Food and Drug Administration for ASC30_39 FDC—a pioneering fixed-dose combo pill...

CREB Unlocks 8.50% APY Bonds for IRA Investors

CRET Broadens the Path to Fixed-Income Security If you're the type who gets a rash just thinking about stock market jitters, pay attention: Compound Real Estate Bonds (CREB) has cracked the door open a bit wider for your retirement peace of mind. They've teamed up with Equity Trust to offer their rock-solid 8.50% APY bonds through self-directed IRAs. That's right—these...

HanAll F&B Maps Bold U.S. Entry with Strategic Pivot

Diving into Uncharted Waters HanAll F&B is setting its sights on the U.S. market, a move that could be make-or-break for this South Korean food manufacturer. With their recent rebranding from Taebaek Sanchae Naengmyeon Farming Association, they're not just changing names—they're shifting operational gears. The name might sound new, but the gutsy ambition behind it is as...

Hansa Bolsters Financials with SERB Deal, Eyes Growth

Financial Gains and Strategic Shifts Oh, here we go again—another quarterly report from Hansa Biopharma, and this one’s got some meat on its bones. They’ve sparked up their financial engine with a hefty €115 million licensing deal with SERB, which is a real shot in the arm. As any investor worth their salt would see, this isn’t just about piling cash. It's...

Brent Crude's Tumult: Oil Giants Weather Market Shifts

Oil Market Faces Uncertain Waves The energy sector's a rough sea these days, with Brent crude prices yo-yoing close to that $100 mark. If you're looking for clarity, don't hold your breath—the EIA's latest report suggests we’re sticking near this price for the foreseeable future before easing into more palatable waters come late 2027. But we ain't there yet, as U.S....

Viatris Engages Investors at Key Healthcare Conferences

Viatris Steps Into the Limelight Across Conferences Investors, listen up—Viatris Inc. is about to spill some beans at a trio of high-stakes healthcare gatherings. Set to rub elbows with the who's who of the biopharma world, this global healthcare crusader's on a mission. They're lining up to have face time at the UBS Global Biopharma Conference, the Jefferies Global...

MOUZ Triumphs at IEM-Beijing 2026, Powered by AutoFull

A Showdown in Beijing: Esports at Its Peak IEM Beijing 2026 wrapped up on November 8, lighting up the Bloomage Biotech•Biohyalux ECM Arena with some high-octane Counter-Strike 2 matches. In a region that's nothing short of a digital battleground, Team MOUZ clinched the crown. And yeah, they didn't just do it solo; they did it seated in style on AutoFull chairs, the...

Modaxo Bolsters Public Transport Support for UITP 2027

Modaxo Steps Up for UITP Summit Hamburg 2027 Well, Modaxo's back at it again, laying down roots in the public transport sector. Fresh off the press, they've announced they'll be a Platinum Partner for the UITP Summit in Hamburg 2027. That's not just a handshake for the cameras, folks. It's a clear shout-out about where they see themselves in this industry. Living Their...

Nielsen's $1.4B Notes to Fuel Bold DoubleVerify Buy

Reading Between the Financial Lines Nielsen's latest move throws a hefty $1.4 billion worth of senior secured notes into the market, aimed at scooping up DoubleVerify in a play that’s as daring as it is dicey. It's the kind of gamble you discuss with your coffee buddy, sipping something strong enough to wake the dead, and exactly the kind of deal that gets seasoned...

PMET's Lithium-Tantalum Study Ups Stakes in Québec Project

Elevated Ambitions in Québec: PMET's Lithium-Tantalum Leap PMET Resources just handed us an intriguing update on their Shaakichiuwaanaan project up in Québec. They're reshaping the roadmap to crank out both lithium and tantalum more efficiently than a bear on a honeycomb. The revised feasibility study has put to paper numbers that have optimists—and skeptics...